Landos Biopharma, Inc.
CIK 0001785345
Revenue (TTM)
$18M
Q1 May 2024
Net Income (TTM)
−$24.71M
+44.2% YoY
Q1 May 2024
EPS Diluted (TTM)
−$3.93
+64.1% YoY
Q1 May 2024
Gross Margin
—
Q1 May 2024
Operating Margin
-141.2%
Q1 May 2024
Net Margin
-137.3%
Q1 May 2024
Free Cash Flow (TTM)
−$45.82M
Q1 May 2024
Cash
$29M
Q1 May 2024
Total Debt
—
Q1 May 2024
Shares Outstanding
3.13M sh
Q1 May 2024
Revenue & Net Income
EPS (Diluted)
Margins
Cash Flow
Revenue Growth (YoY)
No data available for this metric.